-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lu-Satoreotide in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lu-Satoreotide in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lu-Satoreotide in Small-Cell Lung Cancer Drug Details: 177Lu-satoreotide (OPS-201, SOMther)...
-
Product Insights
NewParaganglioma (Glomus Jugulare Tumor) – Drugs In Development, 2024
Empower your strategies with our Paraganglioma (Glomus Jugulare Tumor) – Drugs In Development, 2024 report and make more profitable business decisions. Abnormal growth of chromaffin cells, a type of nerve cell found throughout the body leads to paraganglioma also known as glomus jugulare tumor. It is a rare form of neuroendocrine tumor. These tumors can be found in adrenal glands or outside of it especially in carotid artery. Cause is idiopathic. Headache, high blood pressure, faster pulse rate, sweating is some...
-
Product Insights
NewPheochromocytoma – Drugs In Development, 2024
Empower your strategies with our Pheochromocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL), and neurofibromatosis 1 (NF1). The Pheochromocytoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewMeningioma – Drugs In Development, 2024
Empower your strategies with our Meningioma – Drugs In Development, 2024 report and make more profitable business decisions. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid, and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of...
-
Product Insights
NewNeuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2024 report and make more profitable business decisions. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. These cells produce hormones that regulate various functions in the body. GEP-NETs can be classified as functional or non-functional, depending on whether they secrete excess hormones or not. Functional GEP-NETs can cause various syndromes, such as carcinoid...
-
Product Insights
NewAdrenal Gland Cancer – Drugs In Development, 2024
Empower your strategies with our Adrenal Gland Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal gland cancer is a rare type of neuroendocrine tumor that originates from the cells of the adrenal glands, which are located on top of the kidneys. The adrenal glands produce hormones that regulate various functions in the body, such as blood pressure, metabolism, stress response, and sex drive. Adrenal gland cancer can affect the production of these hormones, causing symptoms...
-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
NewNeuroendocrine Cancer – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Cancer – Drugs In Development, 2024 report and make more profitable business decisions. A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have...
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lu-Satoreotide in Pheochromocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lu-Satoreotide in Pheochromocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lu-Satoreotide in Pheochromocytoma Drug Details: 177Lu-satoreotide (OPS-201, SOMther) is under development for...